DOCETAXEL AND PREDNISON IN ASSOCIATION WITH METRONOMIC THERAPY WITH CICLOPHOSPHAMIDE AND CELECOXIN IN HORMONE-REFRACTORY PROSTATIC CANCER PATIENTS : PHASE II CLINICAL TRIAL WITH PHARMACODYNAMIC AND PHARMACOGENETIC EVALUATIONS - PROMET 2
- Conditions
- PATIENTS WITH PROSTATIC HORMONE-REFRACTORY CANCERMedDRA version: 15.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2006-004478-29-IT
- Lead Sponsor
- G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Male
- Target Recruitment
- Not specified
Inclusion Criteria
DIAGNOSIS OF HORMONE-REFRACTORY PROSTATIC CANCER IN BIOCHIMIC AND/OR CLINIC EVIDENCE OF DISEASE PROGRESSION
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
PREVIOUS CHEMOTHERAPY BUT EXTRAMUSTINE TREATMENT
HEART FAILURE
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method